Vijay Kumar Panthi | Medicine and Health Sciences | Best Researcher Award

Posted on by sciencefather

Mr. Vijay Kumar Panthi | Medicine and Health Sciences | Best Researcher Award

PhD Candidate, Queensland University of Technology, Australia

Vijay Kumar Panthi is a seasoned professional in Pharmaceutics with a focus on drug delivery and formulation. He holds a Master’s degree in Pharmacy (Pharmaceutics) from Mokpo National University, South Korea, and a Bachelor’s degree in Pharmacy from Tribhuvan University, Nepal. With extensive experience in formulation, research, and development, he has worked with several prominent pharmaceutical companies, including Royal Sasa Nepal Pharmaceuticals and Corel Pharmaceuticals. His expertise spans across nanoformulations, drug delivery systems, and formulation development for anticancer and anti-aging treatments. He has also contributed to several publications and conference posters, particularly in the field of nanomedicine, wound healing, and oral drug bioavailability. His research interests center around enhancing drug solubility and permeability, particularly for anticancer and diabetes treatments. He is a registered pharmacist with the Pharmacy Council of Nepal and actively engages in clinical pharmacy training and regulatory affairs.

Profile

Education

Vijay Kumar Panthi completed his Master’s in Pharmacy (Pharmaceutics) from Mokpo National University, South Korea, between 2017-2019. This advanced program deepened his knowledge of drug formulation, nanoformulations, and drug delivery systems. He earned his Bachelor’s degree in Pharmacy from Tribhuvan University, Nepal, at Sunsari Technical College, Dharan, between 2010 and 2014. Additionally, he completed Intermediate studies in Pharmacy at the Nepal Institute of Medical Science and Technology (NIMST), Kathmandu. Before that, he graduated from Mukti Higher Secondary School, Pyuthan, Nepal, in 2005. His academic journey has provided him with a solid foundation in pharmaceutical sciences and research, focusing on developing innovative solutions to improve drug efficacy and bioavailability, particularly in cancer and diabetes therapies.

Experience

Vijay Kumar Panthi has over 10 years of experience in the pharmaceutical industry, spanning formulation development, research, and regulatory affairs. He currently serves as the Manager of Formulation, Research, and Development (FR&D) at Royal Sasa Nepal Pharmaceuticals. Prior to this, he held the same position at Corel Pharmaceuticals Pvt. Ltd., where he developed and tested various drug formulations. His experience also includes conducting formulation and development research at Mokpo National University, South Korea, between 2017 and 2019. Additionally, he worked at Asian Pharmaceuticals Pvt. Ltd., where he contributed to GMP-certified projects, regulatory affairs, and validation processes. He has also participated in industrial training at companies like Everest Pharmaceuticals, Nepal, and Zydus Healthcare, India, which further honed his practical knowledge. Vijay’s diverse experience across multiple pharmaceutical functions highlights his expertise in drug formulation and development, particularly for anticancer and anti-aging applications.

Research Focus

Vijay Kumar Panthi’s primary research interests lie in the formulation of drug delivery systems, particularly for anticancer and diabetes treatments. His work focuses on enhancing the solubility, permeability, and bioavailability of active pharmaceutical ingredients (APIs), particularly those with limited oral bioavailability. In his Master’s thesis, he worked on the co-delivery system of pemetrexed and quercetin via multiple nanoemulsions to improve oral bioavailability and anticancer efficacy. His interest in nanoformulations extends to other therapeutic areas such as wound healing and anti-aging. By utilizing nanoemulsions, liposomes, and hydrogels, Vijay aims to develop novel drug delivery systems that improve the therapeutic outcomes of drugs for various diseases, especially chronic conditions like cancer and diabetes. His research on the formulation of anti-acne treatments and serine protease formulations for inflammation also demonstrates his versatility and commitment to improving patient care through scientific advancements.

Publication Top Notes

  1. Characterization and In Vivo Evaluation of an Oral Multiple Nanoemulsive System for Co-Delivery of Pemetrexed and Quercetin 📚💊
  2. Preparation, Characterization, and Biological Activities of Topical Anti-Aging Ingredients in a Citrus junos Callus Extract 🍊💆‍♂️
  3. Formulation and Development of Adapalene Topical Nanohydrogel Using Different Surfactants and Cosurfactants for Antiacne Activity: In Vitro and Ex Vivo Evaluation 🧴🔬
  4. Enhanced Oral Absorption of Pemetrexed by Ion-Pairing Complex Formation with Deoxycholic Acid Derivative and Multiple Nanoemulsion Formulations 💊🧪
  5. Formulation and Development of Serratiopeptidase Enteric Coated Tablets and Analytical Method Validation by UV Spectroscopy 🧫🔬
  6. A Validated RP-HPLC Method for Simultaneous Determination of Cefixime and Clavulanic Acid Powder in Pediatric Oral Suspension 🧪👶
  7. Preparation and Characterization of Callus Extract From Pyrus pyrifolia and Investigation of Its Effects on Skin Regeneration 🍐🧴
  8. Formulation and Development of Water-in-Oil Emulsion-Based Luliconazole Cream: In Vitro Characterization and Analytical Method Validation by RP-HPLC 🧴🔬

 

 

Stuart Maudsley | Receptor Pharmacology | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Stuart Maudsley | Receptor Pharmacology | Best Researcher Award

Senior Fellow/Professor, H. Lee Moffitt Cancer Center, United States

Dr. Stuart Russell Maudsley is a renowned pharmacologist with a distinguished career in receptor biology, specializing in therapeutic precision medicines targeting GPCRs (G-Protein Coupled Receptors). He is currently the Principal Investigator at the Maudsley Lab and a Senior Member at Moffitt Cancer Center. Dr. Maudsley is also a co-founder of HeptOME, focusing on aging-related diseases and metabolic dysfunction. With over two decades of research experience, he has held prominent roles including scientific advisor to the Belgian Superior Health Council, and various leadership roles at Johns Hopkins, the NIH, and VIB. His groundbreaking work includes receptor pharmacology and molecular biology studies aimed at advancing novel treatments for complex human disorders, particularly cancer and neurodegenerative diseases. His career has been recognized globally, earning numerous awards and honors for his contributions to molecular pharmacology.

Profile

Education

Dr. Stuart Russell Maudsley obtained his PhD in Pharmacology from the University of Leeds, UK, where he was awarded the Ackroyd, Brotherton & Brown Scholarship. His doctoral research focused on electrophysiological and molecular biological studies of Tachykinin receptors, marking the beginning of his illustrious career in receptor pharmacology. Prior to his PhD, Dr. Maudsley earned a First-Class B.Sc. in Pharmacology from the same institution. During his academic tenure, he engaged in advanced studies of ion channel electrophysiology and the pharmacology of the central nervous system, topics that have significantly shaped his subsequent research endeavors. His educational foundation laid the groundwork for his future contributions in both academia and the pharmaceutical industry, particularly in the development of novel therapeutic strategies for neurodegenerative diseases, cancer, and metabolic disorders.

Experience

Dr. Stuart Russell Maudsley boasts an extensive career with leadership roles across academia, industry, and government. He is the Principal Investigator at the Maudsley Lab at Moffitt Cancer Center and the co-founder of HeptOME, where he focuses on receptor-targeted therapies for aging-related metabolic diseases. Throughout his career, Dr. Maudsley has held various significant positions, including Adjunct Director at VIB, Vice-Chair at the University of Antwerp’s Department of Biomedical Science, and Principal Investigator at the NIH. He has contributed to numerous international projects, including his work as a Special Science Advisor to the Belgian Superior Health Council. Dr. Maudsley has also led scientific teams at Johnson & Johnson, the U.S. Department of Defense, and the NIH, where he made crucial contributions to drug development and the understanding of receptor pharmacology. His leadership and expertise have resulted in groundbreaking advancements in the pharmacology and therapeutics of complex diseases.

Awards and Honors

Dr. Stuart Russell Maudsley has received numerous prestigious awards and honors throughout his career. Notable recognitions include the 2021 UAntwerpen Seal of Excellence Grant, 2020 Johnson & Johnson Research Grant, and the 2019 FWO Doctoral Research Grant. He has also been honored with the FWO Senior Research Fellows Grant and the UAntwerpen-IOF Industrial Collaboration Research Grant in 2019. His work in molecular pharmacology and receptor biology has led to the receipt of multiple awards from both European and American institutions, including the National Institutes of Health On-the-Spot Award (2011-2013). Dr. Maudsley’s groundbreaking research on neurodegenerative diseases, aging, and metabolic dysfunction has earned him widespread recognition in the scientific community. His scientific excellence and contributions to pharmacology, drug discovery, and biotechnology continue to inspire advancements in the treatment of complex human disorders.

Research Focus

Dr. Stuart Russell Maudsley’s research primarily focuses on receptor pharmacology, with a special emphasis on G-Protein Coupled Receptors (GPCRs) and their role in human disease. His work seeks to identify and develop precision GPCR-targeted therapies for cancer, neurodegenerative disorders, and metabolic diseases such as obesity and aging-related conditions. Through his leadership in both academic labs and the biotech industry, Dr. Maudsley investigates novel biotechnological platforms, including both wet and dry biomedical technologies. He aims to create multidimensional precision medicines that can more effectively treat complex disorders, particularly those related to aging. His current research in the Maudsley Lab centers on the molecular mechanisms that underlie aging and neurodegenerative diseases, as well as the identification of potential therapeutic agents. By exploring the intricate signaling pathways of GPCRs, Dr. Maudsley is paving the way for the development of innovative treatments for diseases that currently lack effective therapies.

Publications Top Notes

  • β-Arrestin-dependent formation of β2 adrenergic receptor-Src protein kinase complexes – Science (1999) 🧬📚
  • BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders – Trends in Neurosciences (2004) 🧠
  • The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women – International Journal of Obesity (2011) 🍏🏃‍♀️
  • Gonadotropin-releasing hormone receptors – Endocrine Reviews (2004) 💊🔬
  • Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma – Free Radical Biology and Medicine (2007) 🏥
  • Caloric restriction and intermittent fasting: two potential diets for successful brain aging – Ageing Research Reviews (2006) 🧠
  • The β2-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor – Journal of Biological Chemistry (2000) 🧬🔬

 

 

 

Riham Elgogary | Pharmaceutics | Best Researcher Award

Posted on by sciencefatherLeave a Comment on Riham Elgogary | Pharmaceutics | Best Researcher Award

Assoc Prof Dr Riham Elgogary | Pharmaceutics | Best Researcher Award

Assoc Prof Dr Riham Elgogary, Faculty of pharmacy, ain shams university, Egypt

Dr. Riham El-Gogary is an Associate Professor of Pharmaceutics at Ain Shams University’s Faculty of Pharmacy. With extensive experience in pharmaceutical sciences, Dr. El-Gogary has significantly contributed to the field through research and teaching. Her work focuses on advanced drug delivery systems and nanotechnology applications in pharmacology. An active participant in academic and professional circles, she has been recognized for her dedication and excellence in both research and teaching. Her innovative research has led to numerous publications and awards, highlighting her role as a leading figure in pharmaceutics.

Publication Profile

Google Scholar

Strengths for the Award

  1. Strong Academic Background:
    • PhD in Pharmaceutical Sciences (Pharmaceutics) and substantial teaching experience in both undergraduate and postgraduate programs.
  2. Research Expertise:
    • Extensive research contributions in the field of pharmaceutics, including novel drug delivery systems and targeted therapies.
    • High-impact publications in reputable journals such as ACS Nano, Small, and Scientific Reports, indicating significant contributions to pharmaceutical sciences.
  3. Awards and Recognition:
    • Multiple international and national awards for publishing and teaching excellence, including the International Publishing Award from Ain Shams University and travel grants for conferences.
    • Recognition from professional bodies, such as the Egyptian Pharmacist Syndicate.
  4. Grants and Funding:
    • Successfully secured various grants, including research funding from the Missions Department, TWAS/Biovision, and AGYA, demonstrating the ability to attract competitive research funding.
  5. Professional Experience:
    • Active participation in professional committees and involvement in research supervision and practical course preparation, showcasing a well-rounded professional profile.

Areas for Improvement

  1. Publication Metrics:
    • While the researcher has numerous publications, improving the citation impact of some papers could further strengthen their profile. The impact of recent publications such as “Nose-to-brain delivery of 18β-Glycyrrhetinic acid” and “Development and in Vitro/In Vivo Evaluation of Itopride Hydrochloride Expanding Tablets” might be lower, and enhancing their visibility could be beneficial.
  2. Broader Research Impact:
    • Expanding research to include interdisciplinary collaborations or high-impact, emerging areas in pharmaceutics might increase their research visibility and influence.
  3. Leadership and Innovation:
    • Demonstrating leadership in groundbreaking research projects or innovations in pharmaceutics could enhance their candidacy. Engaging in high-profile research initiatives or leading large-scale research collaborations might be advantageous.

Education

Dr. Riham El-Gogary earned her PhD in Pharmaceutical Sciences (Pharmaceutics) from Ain Shams University in August 2014. She completed her M.Sc. in Pharmaceutical Sciences (Pharmaceutics) at the same institution in September 2010. Dr. El-Gogary holds a B.Sc. in Pharmaceutical Sciences from Ain Shams University, awarded in June 2004 with a general grade of “Excellent with Honors.” Her educational foundation is complemented by a diploma from Ramses College for Girls, completed in June 1999.

Experience

Dr. El-Gogary has been an Associate Professor of Pharmaceutics at Ain Shams University since December 2019. Her teaching repertoire includes Physical Pharmacy, Pharmaceutics, Biopharmaceutics, and Dosage Form Design for undergraduates and specialized Pharmaceutics for postgraduates. She has also taught part-time at Misr International University and the British University in Egypt. Additionally, she supervises student research projects and has contributed to the development of practical course materials. Her involvement extends to various committees and professional activities, including disaster management and health and safety.

Awards and Honors

Dr. El-Gogary has received several prestigious awards, including the International Publishing Award from Ain Shams University for multiple years and a Certificate of Excellence in Teaching Pharmaceutics. She was recognized with a partial travel award for conferences in the UK and Spain and received the Armor of Excellence from the Egyptian Pharmacist Syndicate in 2010. Her contributions to faculty accreditation and medical convoys have also been acknowledged with certificates of honor.

Research Focus

Dr. Riham El-Gogary’s research focuses on innovative drug delivery systems, particularly using nanotechnology. Her work includes the development of polymeric nanocapsules for targeted drug delivery, improving therapeutic efficacy for conditions such as cancer and psoriasis. She explores novel formulations like nanoemulgels and micelle-core/chitosan-shell systems. Her research aims to enhance the bioavailability and effectiveness of pharmaceutical agents, addressing significant challenges in drug delivery and therapeutic applications.

Publication Top Notes

  1. Polyethylene Glycol Conjugated Polymeric Nanocapsules for Targeted Delivery of Quercetin to Folate-Expressing Cancer Cells in Vitro and in Vivo – ACS Nano 8 (2), 1384-1401, 2014
  2. Passively Targeted Curcumin-Loaded Pegylated PLGA Nanocapsules for Colon Cancer Therapy In Vivo – Small 11 (36), 4704-4722, 2015
  3. Triple-Modal Imaging of Magnetically-Targeted Nanocapsules in Solid Tumours In Vivo – Theranostics 6 (3), 342, 2016
  4. Polymeric Nanocapsular Baicalin: Chemometric Optimization, Physicochemical Characterization and Mechanistic Anticancer Approaches on Breast Cancer Cell Lines – Scientific Reports 9 (1), 11064, 2019
  5. Novel Antipsoriatic Fluidized Spanlastic Nanovesicles: In Vitro Physicochemical Characterization, Ex Vivo Cutaneous Retention and Exploratory Clinical Therapeutic Efficacy – International Journal of Pharmaceutics 568, 118556, 2019
  6. Fabrication of Rosuvastatin-Loaded Polymeric Nanocapsules: A Promising Modality for Treating Hepatic Cancer Delineated by Apoptotic and Cell Cycle Arrest Assessment – Drug Development and Industrial Pharmacy 45 (1), 55-62, 2019
  7. Ferulic Acid Nanocapsules as a Promising Treatment Modality for Colorectal Cancer: Preparation and In Vitro/In Vivo Appraisal – Life Sciences 298, 120500, 2022
  8. The Beneficial Activity of Curcumin and Resveratrol Loaded in Nanoemulgel for Healing of Burn-Induced Wounds – Journal of Drug Delivery Science and Technology 62, 102360, 2021
  9. Intra-Articular Multifunctional Celecoxib Loaded Hyaluronan Nanocapsules for the Suppression of Inflammation in an Osteoarthritic Rat Model – International Journal of Pharmaceutics 583, 119378, 2020
  10. Angiogenesis and Collagen Promoting Nutraceutical-Loaded Nanovesicles for Wound Healing – Journal of Drug Delivery Science and Technology 56, 101548, 2020

Conclusion

The candidate is highly suitable for the Research for Best Researcher Award due to their strong academic background, substantial research contributions, and recognition in their field. Their extensive publication record, successful acquisition of research grants, and involvement in professional committees showcase their dedication and impact in pharmaceutical sciences. Addressing areas for improvement, such as increasing the citation impact of their work and pursuing interdisciplinary research opportunities, could further bolster their candidacy. Overall, the candidate’s profile aligns well with the award’s criteria, making them a strong contender for the Research for Best Researcher Award.